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Currently, sustained in vivo delivery of active bone morphogenetic protein-2 (BMP-2) protein to 
responsive target cells, such as bone marrow-derived mesenchymal stem cells (BMSCs), remains 
challenging. Ex vivo gene transfer method, while efficient, requires additional operation for cell 
culture and therefore, is not compatible with point-of-care treatment. In this study, two lentiviral gene 
constructs – (1) Lv-BMP/GFP, containing human BMP-2 and green fluorescent protein (GFP) gene (BMP 
group); or (2) Lv-GFP, containing GFP gene (GFP group) – were incorporated with human BMSCs into 
a solution of photocrosslinkable gelatin, which was then subjected to visible light-based projection 
stereolithographic printing to form a scaffold with desired architectures. Upon in vitro culture, 
compared to the GFP group, cells from BMP group showed >1,000-fold higher BMP-2 release, and the 
majority of them stained intensely for alkaline phosphatase activity. Real-time RT-PCR also showed 
dramatically increased expression of osteogenesis marker genes only in the BMP group. 3.5 months 
post-implantation into SCID mice, the micro-computed tomography imaging showed detectable 
mineralized areas only in the BMP group, which was restricted within the scaffolds. Alizarin red staining 
and immunohistochemistry of GFP and osteocalcin further indicated that the grafted hBMSCs, not host 
cells, contributed primarily to the newly formed bone.
Each year, more than 1 million bone fracture patients are hospitalized in the United States, and 5–10% of them 
present delayed healing or nonunion, representing a major clinical challenge in orthopaedic surgery1. Nonunion, 
left untreated, causes pain, limits mobility, and increases healthcare cost2. So far, no effective medications are 
available to directly stimulate intrinsic bone regeneration; a surgical intervention is often required. For example, 
autologous bone graft, a procedure that involves harvesting normal bone tissues from healthy area and implant-
ing into defect sites, has been frequently used and is considered as the “gold standard” for nonunion fractures. 
However, this treatment has several drawbacks, such as donor site morbidity, limited tissue availability, and mold-
ing challenges.
Tissue engineering, an emerging biomedical technology that aims to produce replacement tissues in vitro, 
offers exciting promise to overcome the obstacles of using native tissues. In principle, cell-based bone tissue engi-
neering involves three basic components: osteogenic cells, osteoconductive scaffolds, and osteoinductive growth 
factors3. These components can be used individually or in combination. Irrespective of the approach, it is gener-
ally assumed that a strong osteoinductive cue is critical for successful bone repair. Growth factors known to be 
important for bone development and healing, such as recombinant bone morphogenetic protein-2, 7 (BMP-2, 7), 
platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF), have been applied and 
investigated in the context of bone regeneration, among which BMP-2 is used most widely because of its high 
efficacy in stimulating osteogenesis4. A systematic review reported that addition of BMP-2 significantly increased 
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the efficacy of conventional intervention for the healing of acute open tibia fractures5, and a 44% reduction in 
bone nonunion was also observed6.
Technically, there are 2 main avenues for BMP-2 application: direct administration of BMP-2 protein and indi-
rect administration by introduction of BMP-2 gene into target cells. Due to the short half-life of BMP-2 protein, 
its metabolic clearance in vivo, and the need of continuous osteogenic stimulation for efficacious bone regenera-
tion, the former method requires repeat administration or a large initial dose of BMP-27. For example, without a 
second intervention, up to 12 mg of BMP-2 is needed to heal tibial fractures6, which has resulted in unpredictable, 
severe side effects in some cases, including high rates of nerve root irritation and ectopic bone formation8. Such 
potential risks necessitate the controlled release of BMP-2 or other delivery strategy, such as direct gene transfer of 
BMP-2 gene. Gene delivery can be accomplished virally through adeno-associated virus (AAV) and lentivirus, or 
non-virally in the form of plasmid DNA with different transfection methods9. In comparison to direct adminis-
tration of proteins, BMP-2 gene transduction into cells presents obvious advantages. For example, BMP-2 protein 
is produced endogenously by the resident transduced cells; thus, repeat injection or large dose usage of expensive 
BMP-2 protein is not needed. In addition, the time duration of BMP-2 presence may be controlled by adjusting 
the expression level of BMP-2 gene and the type of delivery vectors.
Currently, ex vivo gene transfer to produce genetically modified stem cells requires the additional process of 
in vitro culture to achieve gene expression in cells, which is costly and requires cell manipulation. In particular, 
the additional cell culture step is incompatible with point-of-care treatment. Therefore, scaffold-mediated gene 
delivery and localized transduction at fracture sites has been proposed as an alternate approach that does not 
involve in vitro cell culture prior to any surgical implantation. Since void- or gap-filling biomaterial scaffolds 
are normally required for the treatment of large bone defects or nonunion, such scaffolds may be easily adopted 
as a carrier system for gene vectors. In 1996, Fang et al.10 reported the use of collagen sponge impregnated with 
plasmid DNA carrying BMP-4 gene for the repair of rat bone nonunion, and showed that some of repair cells 
were transduced by BMP-4 gene, inducing enhanced bone growth. This landmark work, as well as subsequent 
work from other groups, have prompted a new “gene-activated matrix/scaffolds” strategy for augmented bone 
repair11–15. However, most of the reported studies have used naked plasmid cDNA with various carriers, which 
present some advantages such as low immunogenicity and cost-effectiveness, but cellular uptake of these naked 
DNA is generally of poor efficiency16. In particular, plasmid DNAs have low capacity in transducing primary cells 
such as human mesenchymal stem cells (hMSCs), the most promising cell type for bone regeneration. Highest 
plasmid DNA transfection efficiency into human bone marrow MSCs (hBMSCs) was reported to be ≤45% by 
using poly-ethyleneimine as the gene delivery vehicle; however, the process also resulted in more than 20% cell 
death after 72 hours17.
Recently, viral vectors have been used as gene carrier to enhance bone regeneration. For example, 
self-complementary adeno-associated viral (AAV) constructs encoding BMP-2 were coated on a porous polymer 
Poly(ε-caprolactone) scaffold and implanted into critically sized immunocompromised rat femoral defects, which 
were able to transduce hMSCs, leading to significant increases in defect mineral formation as well as mechanical 
properties18. However, the transduction efficiency is relatively low (<10%). In addition, the AAV viral genome 
was diluted during cell dividing because recombinant AAV genomes were present as extrachromosomal forms19. 
In comparison, lentiviral vector is able to efficiently infect both dividing and non-dividing cells, and has been 
widely used to achieve stable gene transduction20. Although lentiviruses have a risk to integrate into the host 
cell genome, integration sites may be more restricted in comparison with other viral vectors, thus reducing the 
risk of insertional mutagenesis21. A recent study reported that lentivirus is able to produce up to 90% transduc-
tion efficiency in hBMSCs, with a long-term gene expression22. Lenti-vector-based genetic engineering of stem 
cell has been used in clinical trials without evidence of vector-induced genotoxicity or other adverse effects23, 24. 
Therefore, we proposed to develop a single-step procedure to co-introduce lentiviral vector containing BMP-2 
gene, together with hBMSCs, into scaffolds without an in vitro pre-transduction process. We hypothesized that 
the simultaneous packaging of regenerative BMP-2 gene and hBMSCs would result in localized gene transduction 
in situ, BMP-2 production, robust osteogenesis, and thus, efficient bone regeneration.
We have recently developed a novel, visible light-based projection stereolithographic technology (VL-PSL)25, 
for the fabrication of customized scaffolds using natural or synthesized biopolymers with precisely controlled 
architecture, thus overcoming the challenges of using more conventional methods. In addition, this new VL-PSL 
procedure allows simultaneous live cell encapsulation, resulting in uniform cellularization throughout the struc-
ture of the scaffolds. Therefore, in this study, we applied VL-PSL to produce gene-activated scaffolds by incor-
porating a lentiviral construct that encodes the human BMP-2 gene and green fluorescent protein (GFP) reporter 
gene (Lv-BMP/GFP) and osteoprogenitor cells into a photocrosslinkable gelatin (mGL) solution, which then 
underwent VL-PSL to form a three-dimensional (3D) hydrogel construct (Fig. 1). hBMSCs were used as the 
osteoprogenitor cells owing to their relatively easy accessibility and high osteogenic capacity upon stimulation by 
osteoinductive factors such as BMP-226. To our knowledge, this is the first report of the application of 3D printing 
technology in fabricating gene- and cell-activated bone scaffolds. We first assessed whether VL-PSL is compatible 
with in situ gene delivery in terms of the viability of viral vectors and target cells. We then tested our hypothesis by 
examining in situ transduction efficiency within construct, endogenous BMP-2 production, and bone formation 
in vitro and in vivo. Our overall goal was to develop a gene- and cell-activated biomaterial scaffold with precisely 
controlled architecture and the capability to enhance bone formation for the treatment of bone defects, including 
nonunion.
Results
Efficiency of ex vivo transduction of Lenti-GFP and Lenti-BMP-2 into hBMSCs. In this study, 
two lentiviral gene constructs were used. The lenti-CMV-BMP-2/GFP (Lv-BMP/GFP) construct contained 
human cytomegalovirus (CMV) immediate early promoter driven a full length of human BMP-2 gene (1.2 kB) 
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followed by an internal ribosome entry site (IRES) and a GFP reporter gene to allow monitoring of gene trans-
fer efficiency. A lenti-CMV-GFP (Lv-GFP) construct carrying only the GFP reporter gene served as the control 
(see Supplementary Fig. S1A). Using a conventional ex vivo transduction procedure on 2D cultures of hBMSCs, 
green fluorescence was observed as early as 48 hours in either Lv-GFP or Lv-BMP/GFP transduced cells (see 
Supplementary Fig. S1B). Equal efficiency (~85%) was observed in the two groups. To analyze the osteoinductive 
effect of the expression of BMP-2 gene, the activity of alkaline phosphatase (ALP) in hBMSCs, an early marker of 
osteogenesis, was assessed 7 days post-transduction. High enzymatic activity of ALP, as seen by strong histochem-
ical staining (purple), was observed only in the Lv-BMP/GFP group (see Supplementary Fig. S1C), indicating the 
functional bioactivity of the BMP-2 produced after gene transduction.
In vitro characterization of constructs produced by single-step fabrication. hBMSCs were intro-
duced with either Lv-BMP/GFP (BMP group) or Lv-GFP (GFP group) to the mGL solution, and were encapsu-
lated into the hydrogel scaffolds in a single step, using a VL-PSL 3D printing technology previously developed 
(Fig. 1)23. As shown in Fig. 2A,B and C, VL-PSL was able to produce hydrogel constructs with different archi-
tectures and porous infrastructures. More importantly, GFP expression was observed in both groups and the 
transduction efficiency in both groups was similar at ~65–80 percent (Figs 2D,F, S4). We also observed that cell 
distribution was uniform within the construct and conformed to the scaffold geometry as well. For example, no 
cells were seen in the pores, (Fig. 2E,G), as designed.
BMP-2 secretion from constructs in BMP group. The expression of the transduced BMP-2 in the 3D 
constructs was analyzed next. Cell laden scaffolds were cultured in basal growth medium for 4 days, and then 
the BMP-2 concentration in the medium was measured by enzyme-linked immunosorbent assay (ELISA). In the 
BMP group, BMP-2 concentrations were at 5–15 ng/ml (Fig. 3), which was within the range of BMP-2 concen-
trations (~10 ng/ml) often used to induce BMSCs osteogenesis in vitro27, 28. In contrast, in the GFP control group, 
the level of BMP-2 protein was at the undetectable range, which was expected since BMP-2 was not supplemented 
into the culture medium.
Robust osteogenesis in BMP group constructs. After 14 days in culture, the constructs were histo-
chemically stained in toto for ALP activity, detectable as purple staining (Fig. 4A). In the BMP group, most cells 
appeared densely stained throughout the scaffolds, while cells in the GFP control group showed poor staining, 
clearly indicating the substantially higher activity of ALP in cells of the BMP constructs. After 4 weeks in cul-
ture, real time RT-PCR was employed to analyze the expression of osteogenic marker genes in both groups. 
The expression of Runt-related transcription factor 2 (RUNX2), Collagen type I (COL 1), Osteocalcin (OCN) and 
Bone sialoprotein (BSPII) genes were significantly higher in the BMP group, compared to those in GFP control 
group (Fig. 4B). Osteocalcin immunohistochemistry further confirmed its deposition within the BMP constructs 
(Fig. 4C). We also examined whether the higher level of extracellular matrix production in the BMP group con-
structs would contribute to higher mechanical properties. We measured the compressive moduli of scaffolds in 
both groups at culture day 35, and found that the BMP group constructs became stiffer with time with ~90% 
higher compressive modulus than those in the GFP control group (see Supplementary Fig. S2). Taken together, 
these results indicate that hBMSCs encapsulated within the BMP group constructs underwent robust osteogene-
sis, which was not seen in the GFP group.
Assessment of in vivo ectopic bone formation capacity of VL-PSL fabricated, hBMSC-seeded 
constructs. After fabrication, the constructs from the BMP and GFP groups were immediately and individu-
ally implanted into the hindlimb musculature of SCID mice. At 3.5 months post-implantation, micro-computed 
tomography (µ-CT) imaging showed detectable mineralized areas in the BMP group, suggesting ectopic bone 
formation in muscle (Fig. 5A), which were absent in the GFP control implants. The implants were harvested 
and then processed for biochemical, mechanical, and histological analyses. For histology, the samples were pro-
cessed without de-calcification. In agreement with the μ-CT imaging results, the total calcium content of the 
BMP group was 3.6 μg/construct, substantially higher than that of the GFP group (0.08 μg/construct; Fig. 5B, 
p < 0.01). Constructs in the BMP group also exhibited stronger mechanical property with a compressive modulus 
of 350 kPa (Fig. 5C, p < 0.01), which is significantly higher than the constructs right before implantation (35kPa). 
Such enhancement could have resulted from the higher content of calcium and extracellular matrix. In compari-
son, the stiffness of the GFP group implants was low and unchanged with time.
As shown in Fig. 6, there was no apparent sign of host tissue reaction, indicated by minimal ingrowth of host 
tissue and blood vessels, which was further confirmed by H&E staining (see Supplementary Fig. S3). Alizarin 
Figure 1. One-step VL-PSL fabrication of engineered bone consisting of photocrosslinked methacrylated 
gelatin (mGL) encapsulating hBMSCs and lentiviral BMP-2/GFP vector constructs (Lv-BMP/GFP).
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red staining was employed to assess the spatial distribution of tissue mineralization, and the results showed that 
robust positive staining (red) was only seen in the BMP group (Fig. 6A,B), in agreement with the results from 
μ-CT imaging. It is noteworthy that calcium deposition was localized only to the center of the construct rather 
than its margin, suggesting localized bone formation within the implant without outgrowth or contribution from 
host cells.
To assess whether the mineralization observed was a result of genuine osteogenic differentiation and ossifica-
tion, immunohistochemistry was performed to detect osteocalcin, a bone cell specific marker. Positive osteocalcin 
Figure 2. VL-PSL based fabrication of hydrogel scaffolds suitable for cell encapsulation. (A) Solid hexagonal, 
cylindrical and cubic mGL scaffolds or (B and C) porous scaffolds made with VL-PSL. (D–G) Lentiviral gene 
transduced hBMSCs encapsulated within solid (D, F) or porous (E, G) hydrogel scaffold. On culture day 2 post 
fabrication, GFP expression was detected based on fluorescence imaging in constructs from the GFP  
(D and E) or BMP (F and G) groups. Circles in E & G denote the absence of cells in the pores within the 
scaffold. Bar = 10 mm in A, 2 mm in B and C, and 200 μm in (D–G).
Figure 3. Production of BMP-2 by hBMSCs encapsulated in gene-activated hydrogel scaffolds. Conditioned 
medium was collected from culture day 4–8 and assayed for BMP-2 by ELISA. The results showed BMP-2 
production only in cultures of the BMP group. **p < 0.01.
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staining was clearly seen only in the BMP group (Fig. 6D,E), but not in the GFP group (Fig. 6C), indicating oste-
ogenesis and the presence of osteoblasts within the BMP-2 gene-loaded constructs.
The fact that osteogenesis was only observed within the center area of the implanted constructs (Fig. 6B,D,E) 
suggested that the transplanted hBMSCs were likely to be the key contributing cell population in this process. 
This was examined by exploiting the presence of the GFP reporter gene in the lentiviral BMP-2 gene construct 
(see Supplementary Fig. S1), resulting in expression of both GFP and BMP-2, and allowing the tracing of the 
transduced cells using GFP as a marker. We then performed GFP immunohistochemistry to trace the distribu-
tion of the transduced hBMSCs. As shown in Fig. 6F, the peripheral area of the constructs showed very weak 
GFP staining, while the most GFP-positive cells were observed in the center of the constructs, indicating either 
a higher level of gene transduction or abundance of transduced cells, or both, in the center. This distribution of 
GFP staining roughly coincided with that of osteocalcin immunostaining and alizarin red positive areas, strongly 
suggesting that the implanted hBMSCs, not host cells, were the major contributing cell population to osteogenesis 
and bone formation in the implanted constructs in vivo.
Figure 4. Assessment of osteogenic differentiation of hBMSCs encapsulated in gene-activated hydrogel. 
(A) ALP staining at day 14 post fabrication. Purple staining of ALP activity was only seen in the BMP group. 
Bar = 100 μm. (B) Real-time RT-PCR analysis of expression of osteogenic genes at day 28. All results were 
expressed relative to the level at day 0. RUNX2, Runt-related transcription factor 2; COL1, collagen type I; OCN, 
osteocalcin; and BSP2, bone sialoprotein II. Expression of all osteogenesis-associated genes was significantly 
higher in the BMP group compared to GFP group (**p < 0.01) (C) Osteocalcin immunohistochemistry. Brown 
staining of osteocalcin was detected only in the BMP group. Bar = 100 μm.
Figure 5. Assessment of ectopic bone formation upon intramuscular implantation of hBMSC-seeded, gene-
activated constructs at 3.5 months after implantation. (A) µCT imaging of BMP group, showing mineralization 
sites consistent with ectopic bone formation (indicated with yellow arrows and white rectangular frames). (B) 
Quantitation of calcium deposition in constructs showed significant mineralization only in the BMP group. (C) 
Mechanical testing indicated significantly elevated compressive Young’s modulus in the implanted constructs of 
the BMP group, suggesting robust bone matrix deposition. **p < 0.01.
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Discussion
Our study reported here has critically extended the potential of gene-activated matrix as a bone repair method-
ology by developing a gene- and cell-activated customized scaffold, produced by combining a rapid 3D printing 
technology with viral vector-based gene delivery and stem cell based tissue engineering through a single-step 
procedure.
Gene-activated matrices have been studied extensively since the first report about two decades ago10. In most 
subsequent studies, the purpose of gene delivery was to release gene harboring vectors from the matrix to trans-
duce host cells. The advantages and disadvantages of this strategy, for example, for bone formation, are obvious. 
The method is simple and does not require cell transplantation, and in vitro cell harvest and additional culture 
process are not necessary. However, since host cells need to migrate into the scaffold from the surrounding tissues 
to allow gene transduction, the introduced gene constructs are likely to diffuse out of the scaffold during this time, 
resulting in out-of-scaffold gene delivery and transgene (e.g., BMP-2) expression, and finally, the unregulated 
bone formation29. In addition, the gene transduction and osteogenesis that starts from the edge or margin of the 
implants may result in reduced or delayed bone formation in the center area, a complication often observed in 
bone nonunion. Therefore, for effective application of gene-activated matrices for bone formation, it is important 
to control the amount and location of the expressed BMP-2 and the newly formed bone. Controlled release of 
gene constructs has been applied, but did not solve the problem completely30. To address these requirements, 
we have designed a method for in situ scaffold-mediated stem cell engineering by transplanting progenitor cells 
simultaneously with desired viral gene vectors, thus allowing in situ uptake of virus and gene transfer to control 
transduction within the scaffold structure, limiting vector release and undesirable bone formation outside of the 
implanted graft.
The engineered biomaterial scaffold architecture is known to play an important role in modulating bone 
regeneration and determining the final anatomical aspects of the repaired bone31. For example, a 0°/90° alignment 
of the scaffold fibers demonstrated a significantly improved bone regeneration32, 33. Thus, a scaffold fabrication 
method with customizable capacity is desirable. Currently, there are several different solid freeform fabrication 
technologies (3D printing) that allow for precise scaffold production based on computer-aided design (CAD) 
models or clinical imaging. However, not all of them support live cell incorporation. In addition, due to the 
known sensitivity of DNA to ultraviolet (UV) illumination, i.e., DNA damage resulting from UV-initiated pyrim-
idine dimerization, fabrication methods using UV as the polymerization trigger are, in principle, incompatible 
with DNA-based matrix activation. The VL-PSL method employed here utilizes visible light23, thus removing the 
risk of compromising cell viability25, 34, 35, or damaging the activity of the viral vectors; this is confirmed by our 
results showing the viability and infectivity of viral vectors after the VL-PSL process.
To further control a burst release of viral vectors from the biomaterial, a hydrogel scaffold with nano-pores is 
desired to reduce free diffusion, compared to other scaffolds with larger pores30, 36. For this purpose, we have cho-
sen gelatin hydrogel, fabricated by VL-PSL, as the biomaterial because of its biocompatibility and osteoconductive 
capacity37–39. It is also biodegradable, therefore allowing tissue remodeling for new bone formation. A limitation 
Figure 6. Histological and immunohistochemical examination of ectopic bone formation in intramuscular 
implants of hBMSC-seeded, gene-activated constructs at 3.5 months post-implantation. (A,B) Alizarin 
red staining revealed abundant mineralization in (B) BMP group, but absent in (A) GFP group. (C, 
D,E) Osteocalcin immunohistochemistry detected absence of staining in (C) GFP group, but positive 
staining in (D,E) BMP group, specifically in the center of the implant, compared to the margin. (F) GFP 
immunohistochemistry showing localization of gene-transduced hBMSCs primarily at the center of the 
implant, coinciding with the expression of osteocalcin. Bar = 100 μm.
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of gelatin is its low mechanical strength (~30 kPa compressive modulus), although robust osteogenesis may com-
pensate in part for this insufficiency, since enhancement of the mechanical strength of the gelatin constructs was 
observed in the BMP group in our in vivo study (Fig. 5D). Recently, we have incorporated poly-D,L-lactic acid/
polyethylene glycol/poly-D,L-lactic acid (PDLLA-PEG) in VL-PSL for live cell fabrication, and produced con-
structs exhibiting much stronger mechanical property (>800 kPa compressive modulus)35. However, whether 
such gel scaffolds support osteogenesis is unknown and will be tested in our future work.
Although lentiviral vectors are not completely devoid of the risk of oncogenicity, no apparent adverse effects 
with the use of lentiviral vectors have been reported in clinical trials23, 24, 40, 41. In addition, lentiviral vectors are 
highly efficient in transducing primary hBMSCs in comparison to AAV18, 42. In our study, the average level of 
BMP-2 production was 10 ng/ml from 1 × 106 cells in 5 days, which is sufficient to induce hBMSC osteogenesis. 
In comparison, a study using AAV as the carrier reported a highest BMP-2 concentration at 2 ng/ml18. We are 
unable to identify directly comparable studies, but one group using goat BMSCs and non-viral BMP-2 vectors 
reported 8 ng/ml BMP-2 production from 1 × 106 cells in 14 days43, illustrating the high transfection efficiency 
of our method. Using our method, after 3 months of culture, BMP-2 production by hBMSCs is still detectable, 
although the level has decreased to 1.3 ng/ml/1 × 106 cells.
In previous reports using scaffolds loaded with BMP-2 protein or BMP-2 expressing cells, the majority of bone 
formation is often occurs at the margin areas; in these instances, the location of the excessive bone formation may 
function as a physical barrier to delay or impair the ossification process in the interior regions of the grafts44, 45. 
In the current in vitro study, uniform bone formation (indicated by ALP staining) throughout the construct was 
observed, representing a more desirable process of bone formation. However, it is interesting to note that our in 
vivo results show higher level of osteogenesis and GFP immunostaining localized at the center instead of at the 
margin of the implanted construct, which could have resulted from the difference between in vitro and in vivo 
culture conditions. In the in vitro study, the released virus stayed in the medium, resulting in saturated viral con-
centration in the margin, sufficient to infect the remaining cells. On the other hand, under in vivo conditions, the 
released virus may be quickly cleared by the body, leading to continuous release of AAV from the implant and less 
bone formation at the margin. Also, since no observable bone formation is seen outside of the scaffold implants, 
it is reasonable to assume that the amount of released lentiviral particles is insufficient to transduce the host cells 
surrounding the implant. Our recent in vitro results obtained a Transwell co-culture set-up show only limited 
gene transduction of cells after being exposed to the conditioned medium of GFP or BMP-loaded scaffolds (data 
not shown); effective gene transduction of hBMSCs only takes place in-scaffold, likely because of the depend-
ence on a sufficient level viral gene construct. In addition, we observe similar spatial distribution of Alizarin red 
and GFP positive area, indicating that the formation of new bone involves primarily transplanted cells. Taken 
together, we conclude that the bulk of the viral load is locally transduced into the seeded hBMSCs within the scaf-
fold, without burst release from the scaffolds, which reduces the risk of uncontrolled bone formation. Therefore, 
the gene and cell-activated construct developed here is a promising and likely safe method to achieve localized 
and homogeneous bone formation.
It should be pointed out that the in vivo bone formation observed here is relatively slow with little vascular-
ization (Figs 6 and S3), which could impair long-term integration between the neo-bone graft and host tissue. 
In our previous study, we have shown that angiogenesis resulting from viral-vector-based vascular endothelial 
growth factor (VEGF) transduction is important for enhancement of the regenerative potential of stem cells46. A 
possible reason is that the gene-activated scaffold is applied without the continuous presence of agents, such as 
Polybrene47, that are commonly used to enhance virus absorption and gene transfer efficiency, which may pres-
ent potential safety risks for clinical application48, 49. As a result, we did not achieve a level of BMP-2 production 
similar to that in vitro; future optimization of viral load and judicious formulation of virus adsorption enhancing 
cocktails may accelerate this process. The paucity of blood vessels in the constructs, which would limit host cell 
invasion, may be addressed in the future by co-introducing viral gene constructs of other osteoinductive factors, 
such as VEGF, together with BMP-250.
Conclusions
We have developed a single-step, BMP-2 gene-activated, live cell encapsulated scaffold fabrication procedure for 
bone formation. Efficient transgene expression (GFP and BMP-2) is seen in hBMSCs encapsulated in the engi-
neered scaffolds. Cell distribution is uniform within the construct and conforms to scaffold geometry. Results 
from ELISA, real time RT-PCR, immunohistochemistry, and mechanical testing all indicate robust osteogene-
sis within constructs activated with lentiviral BMP-2 vector, without the supplementation of exogenous BMP-2 
protein. After intramuscular implantation in SCID mice, μ-CT imaging showed detectable mineralized areas in 
the BMP group, suggesting effective ectopic bone formation in vivo, which is absent in the GFP control group. 
In addition, formation of the new bone is localized and restricted within the implanted scaffolds and is primarily 
associated with the transplanted GFP-labeled hBMSCs, based on coincident staining of osteocalcin and GFP.
Materials and Methods
Materials. All reagents used in this study were purchased from Sigma-Aldrich (San Luis, MO), unless oth-
erwise stated.
Isolation and expansion of hBMSCs. hBMSCs were isolated from bone marrow aspirates obtained 
during total joint arthroplasty using a previous protocol established in our laboratory51 with IRB approval and 
informed patient consent (University of Washington and University of Pittsburgh). The stemness of hBMSCs was 
tested by colony forming efficiency and mesoderm differentiation capability (osteogenesis, chondrogenesis, and 
adipogenesis, data not shown). Passage 3 (P3) hBMSCs were used in this study by pooling cells from 3 patients 
(55-year-old male, 67-year-old female, and 81-year-old male).
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Lentiviral vector preparation. The lenti-CMV-BMP-2/GFP (Lv-BMP/GFP) construct contains human 
cytomegalovirus (CMV) immediate early promoter driven full length human BMP-2 gene (1.2 kB) followed by 
an internal ribosome entry site (IRES) and a GFP reporter gene to allow monitoring of gene transfer efficiency by 
green fluorescence. A lenti-CMV-GFP (Lv-GFP) construct carrying only the GFP reporter gene served as control 
(see Supplementary Fig. S1A). Lenti-viral vectors were produced according to the standard protocol52.
Functional testing of lentiviral BMP-2 construct by ex vivo transduction into hBMSCs. P3 
hBMSCs were expanded to 80% confluency and the medium was switched to serum free DMEM medium con-
taining lentiviral vectors (total 2 × 106). Sixteen hours after infection, the culture medium was replaced with fresh 
growth medium (GM, DMEM supplemented with 10% fetal bovine serum, FBS). GFP expression was observed 
and imaged using an epifluorescence microscope (CKX41, Olympus, Japan) equipped with a color camera 
(DFC321, Leica, Germany) at 48 hours post-infection. Expression of alkaline phosphatase (ALP) in hBMSCs 
was qualitatively analyzed at 14 days after infection by ALP histochemical staining using a Leukocyte Alkaline 
Phosphatase Kit (86 R, Sigma) following the manufacturer’s protocol. Briefly, the culture medium was removed 
and staining solution was added and incubated with cells at 37 °C for 1 hour. Stained cultures were observed and 
imaged using a DSL camera (T3i, Canon, Japan).
Preparation of materials for visible light-based stereolithography (VL-PSL). Methacrylated gel-
atin (mGL), serving as the monomer for VL-PSL, was prepared as described previously39. Briefly, 3% aqueous 
gelatin solution was reacted with methacrylic anhydride for 16 hours, dialyzed extensively against H2O to remove 
unreacted reagents, lyophilized, and kept in dark until use. The visible light activated photoinitiator, lithium 
phenyl-2,4,6-trimethylbenzoylphosphinate (LAP), was synthesized by reacting dimethyl phenylphosphonite 
(Acros Organics, New Jersey) with 2,4,6-trimethylbenzoyl chloride via a Michaelis-Arbuzov reaction53.
Single step VL-PSL. A customized stereolithographic apparatus (EnvisionTec, Germany) was used 
for VL-PSL using parameters optimized in our previous study25. 10% mGL (w/v) and 0.6% LAP (w/v) 
were dissolved in 30 ml HBSS (Ca & Mg+) completely and adjusted to pH 7.4 with sodium hydroxide. 
Insulin-Transferrin-Selenium (ITS - 10 mg/L insulin, 5.5 mg/L transferrin, and 6.7 μg/ml sodium selenite; 
Invitrogen) and Polybrene (8 µg/mL) were added to maintain cell viability and virus infection ability, respectively, 
under serum free condition. hBMSCs (5 × 106 cells/ml final cell density) were then mixed into the gelatin solution 
together with lenti-GFP or lenti-BMP-2/GFP viral constructs (1 × 108 for each).
The cell suspension was poured onto the plate and VL-PSL started using a procedure that we have previously 
established25. Solid hexagonal, cylindrical, and cubic models or a porous cylindrical model (with 500 μm diam-
eter tubes passing top-to-bottom through the structure and 2 mm distance between the closest edges of any two 
tubes) were used as the templates for fabrication. To maintain consistency in quantitative assays, a solid cylin-
drical 3D model (5 mm diameter and 2 mm height) was used to make constructs for all subsequent experiments. 
After VL-PSL, the solidified scaffolds were taken off the platform and transferred to growth medium (10% FBS), 
supplemented with Polybrene, but without antibiotics for 4 hours. Afterwards, the medium was removed and 
replaced with fresh, full growth medium. The medium was changed every 3 days, up to 35 days. The constructs 
containing lenti-GFP or lenti-BMP-2/ GFP vectors were named as the GFP group or BMP group, respectively.
Gene transfer efficiency within the 3D construct was assessed after 2 days on the basis of GFP fluorescence. 
Microscopic fields obtained by fluorescence (GFP) and phase contrast imaging were merged to determine infec-
tion efficiency (see Supplementary Fig. S4). Specifically, the number of fluorescent, GFP-positive cells detected 
by fluorescence microscopy was expressed as a percentage of the total number of cells detected by phase contrast 
microscopy.
BMP-2 quantitation. Cylindrical constructs (5 mm diameter and 2 mm height) were individually cultured 
in 200 µl GM. On day 4, the medium was replaced with fresh GM and constructs were cultured for 4 additional 
days. BMP-2 accumulation in the culture medium during this period, produced by the transduced hBMSCs, was 
quantified using a BMP-2 Quantikine ELISA Kit (R&D, Minneapolis, MN).
Alkaline phosphatase (ALP) staining. At day 14 post-fabrication, ALP expression in hBMSCs encapsu-
lated within the gelatin constructs were histochemically assessed as described above. Briefly, the cultured con-
structs were removed from culture medium and immersed into the staining solution and incubated at 37 °C for 
1 hour. The macroscopic and microscopic appearance of stained constructs was imaged using a DSL camera 
(T3i, Canon, Japan) or a microscope (CKX41, Olympus, Japan) equipped with a color camera (DFC321, Leica, 
Germany).
Real-time quantitative reverse transcription polymerase chain reaction (real time 
RT-PCR). Expression of osteogenic genes in hBMSCs was analyzed with real time RT-PCR after 28 days 
in vitro culture. Constructs from GFP or BMP groups were washed 3 times with HBSS, placed into Trizol 
(Invitrogen), and ground with a plastic pestle. Total RNA was extracted into the aqueous layer after adding chlo-
roform and purified using an RNeasy Plus Mini Kit (Qiagen, Maryland). Real time RT-PCR was performed using 
the SYBR Green-based method and a real-time PCR system (StepOne Plus, Applied Biosystems). Expression 
levels of osteogenesis-related genes such as Runt-related transcription factor 2 (RUNX2), collagen type I (COL1), 
osteocalcin (OCN), and bone sialoprotein II (BSP2) were analyzed by the 2−ΔΔct method with 18 S rRNA as the 
control housekeeping gene.
Histological analysis. Samples were fixed in 10% buffered formaldehyde (Fisher Chemicals, Fari Lawn, NJ), 
dehydrated in a series of ethanol baths (70, 95 and 100%) and finally in xylene, and embedded in paraffin. Tissue 
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blocks were sectioned at 6 μm thickness using a standard microtome (Leica Biosystems, France), which were then 
subjected to standard H&E staining and imaged with a CKX41 microscope (Olympus, Japan) equipped with a 
Leica DFC 3200 camera.
Osteocalcin immunohistochemistry. The extent of osteogenesis was further assessed based on immuno-
histochemical staining of osteocalcin. Briefly, histological sections were subjected to antigen retrieval by treatment 
with chondroitinase ABC (100 mU/ml) and hyaluronidase (250 U/ml), peroxidase blocking in 3% H2O2, and fur-
ther blocked in 1% horse serum. Primary antibody (rabbit anti-osteocalcin; abcam ab93876, 1:200) was applied 
to the section, followed by overnight incubation at 4 °C. Detection of primary antibody was performed with bioti-
nylated goat anti-rabbit antibodies (Vector Laboratories, Burlingame, CA). Secondary peroxidase-conjugated 
antibodies were visualized using a Vectorstain Elite ABC and developed with the VIP kit (Vector Laboratories). 
Sections were counterstained with hematoxylin prior to mounting. Images were captured with a CKX41 micro-
scope (Olympus, Japan) equipped with a Leica DFC 3200 camera.
Mechanical testing. At culture day 35, the compressive moduli of constructs in the GFP and BMP groups 
were assessed using a mechanical tester (ElectroForce 3200, Bose). Constructs were placed between two metal 
plates and compressed to 20% of original thickness (0.4 mm) with the force recorded. Compressive Young’s mod-
ulus was determined from the linear area in the stress/strain curve.
Intramuscular implantation of constructs. Female Severe Combined Immunodeficiency (CB17/
Icr-Prkdcscid/IcrIcoCrl SCID®) mice (8–12 weeks old; Charles River Laboratories; Wilmington, MA) were used 
according to University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) approved proto-
cols. All experiments were performed in accordance with relevant guidelines and regulations. Prior to surgery, the 
hind legs of the animals were shaved on both sides and cleansed with alcohol. A skin incision (around 6 mm long) 
was made to reveal the muscles of the upper long bone. Blunt dissection of the muscles was carefully performed 
to create pockets for the constructs without making traumatic damage to the muscle tissues. Constructs from 
the GFP or BMP group (n = 6 for each group) were then inserted into the muscle on both sides of the hind legs. 
Polybrene was not included for the in vivo study due to potential safety issue in the future clinical application48, 49. 
The muscles and skin of the animals were then individually and sequentially sutured.
Micro–computed tomography (µCT). At 3.5 months after implantation, the mice were anesthetized and 
scanned at 14 μm resolution with a commercial μ-CT system (Scanco vivaCT 40, Switzerland). Three-dimensional 
reconstructions of detectable mineralized tissue in implantation site were created at 29 μm resolution for analyti-
cal visualization. A volume of interest was defined for each specimen, and a threshold was chosen to exclude any 
non-mineralized tissue. The total volume and density of bone was then determined.
Measurement of total calcium content. The animals were sacrificed at 3.5 months post-implantation 
and the implants were harvested. After clearing of adventitious muscle tissues, the constructs were soaked in 1 ml 
1 N HCl and ground thoroughly. After extraction for 3 days at room temperature, the solution was cleared by cen-
trifugation at 12,000 g for 5 minutes and the calcium concentration was measured using a calcium colorimetric 
assay kit (BioVision, San Francisco, CA), and total calcium deposition in each construct was calculated.
Alizarin red staining. Calcium deposition in the implants was further examined histologically by Alizarin 
Red S staining (Rowley Biochemical, Danvers, MA) and then imaged with a CKX41 microscope (Olympus, 
Japan) equipped with a Leica DFC 3200 camera.
GFP Immunohistochemistry. To analyze the distribution of implanted hBMSCs, on the basis of their 
transduction by lentiviral vectors containing GFP, immunohistochemistry was performed using rabbit antibodies 
directed against GFP (Abcam, ab6556; 1:500) using the procedure described above for osteocalcin.
Statistics. All experiments were performed in triplicates. All results are presented as means ± standard devi-
ation and analyzed using paired t-test with statistical significance set at p-value < 0.05. In all cases, * was used for 
p < 0.05, and ** for p < 0.01.
Data availability. The datasets generated from the current study are available from the corresponding author 
upon reasonable request.
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